(Incyte, 8 Weeks)
(Incyte, 8 Weeks)
Sadick Research Group is conducting a clinical study of adolescents and adults receiving topical treatment for atopic dermatitis (eczema).
Gender: Male and Female
Minimum Age: 12 Years Old
Maximum Age: N/A
Facility Type: Outpatient
Stipend Range: Up to $200 Upon Study Completion
Study Length: 8 weeks
Sponsor: Incyte Corporation
This is a double-blind, randomized, 8 week, vehicle-controlled efficacy and safety study of Ruxolitinib cream followed by a long-term safety extension period in adolescents and adults with atopic dermatitis. All enrolled subjects will receive a topical medication to be applied daily for 8 weeks. There are 9 office visits throughout the study which may include a physical exam, blood draws, urine sampling, assessments by qualified professionals and other assessments which will be reviewed in detail at your screening visit. At the end of the 8 week study period, participants will have the option to continue receiving treatment in a long-term extension study. All services are provided at no cost.
Inclusion and Exclusion Criteria
Eligible male and female participants will be 12 years of age or older, have a diagnosis of mild to moderate eczema for at least two years, and have at least 1 lesion (patch of eczema) currently flaring. Female subjects cannot plan to be pregnant or breast feeding during the study. Subjects must be available for the 9 office visits during the study and be willing to comply with all study instructions. Several other restrictions and criteria may apply that the study doctor will review with you to determine if you qualify to enter the study.
Other Trial Details
- Physical exam and assessments of study condition to be provided at no cost by an experienced provider.
- No insurance necessary.
- Compensation will be provided at the end of study participation.